AlginMD - Cognitive Health Panel

Alzheimer’s Disease Risk & Cognitive Decline Panel

Early detection of Alzheimer's disease is possible years before symptoms begin. Our comprehensive panel combines genetic, molecular, and biomarker analysis with reversible cause screening — empowering you and your clinician to take proactive steps against cognitive decline.

Genetic Risk Marker

APOE Genotype
- ε4 allele increases risk of late-onset Alzheimer’s disease.
- Useful for risk stratification and counseling, but not deterministic.

ATN Profile (Core Alzheimer’s Biomarkers)

A = Amyloid
- Aβ42, Aβ40, and Aβ42/40 ratio (plasma or CSF)
- Low ratio suggests amyloid accumulation.
T = Tau
- p-tau181 (or p-tau217, p-tau231 if available)
- Elevated levels are highly specific for Alzheimer’s pathology.
N = Neurodegeneration
- NfL (Neurofilament Light Chain)
- MRI volumetrics (hippocampal atrophy) or FDG-PET optional.

Reversible / Secondary Causes of Cognitive Impairment

Thyroid
- TSH (hypothyroidism can mimic dementia).
Infectious
- RPR (syphilis serology).
- Lyme antibody panel (Borrelia infection can cause cognitive issues).
- ANA (antinuclear antibody) — screens for autoimmune/inflammatory causes.
Nutritional / Metabolic
- B12
- Methylmalonic Acid (MMA) — more sensitive indicator of functional B12 deficiency.
- ESR (Sedimentation Rate) — marker of systemic inflammation.

Clinical Use

Baseline risk stratification: APOE + ATN profile.
Rule out treatable causes: thyroid, B12, infections, autoimmune.
Guide intervention: tailor prevention (lifestyle, vascular risk control, supplements, clinical trial eligibility).

Know your cognitive future—years ahead

Includes APOE genotyping, inflammatory markers, and neuro-aging analysis for early intervention and prevention.

Investment: $1000–$2,500

Benefit: Ideal for individuals with family history or cognitive concerns.

Select referring doctor: